FCGR3B Blocking Peptide (N-term)
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O75015 |
---|
Gene ID | 2215 |
---|---|
Other Names | Low affinity immunoglobulin gamma Fc region receptor III-B, Fc-gamma RIII-beta, Fc-gamma RIII, Fc-gamma RIIIb, FcRIII, FcRIIIb, FcR-10, IgG Fc receptor III-1, CD16b, FCGR3B, CD16B, FCG3, FCGR3, IGFR3 |
Target/Specificity | The synthetic peptide sequence is selected from aa 32-47 of HUMAN FCGR3B |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | FCGR3B |
---|---|
Synonyms | CD16B, FCG3, FCGR3, IGFR3 |
Function | Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils. |
Cellular Location | Cell membrane; Lipid-anchor, GPI-anchor. Secreted Note=Secreted after cleavage |
Tissue Location | Expressed specifically by polymorphonuclear leukocytes (neutrophils). Also expressed by stimulated eosinophils |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
References
Ravetch J.V.,et al.J. Exp. Med. 170:481-497(1989).
Simmons D.,et al.Nature 333:568-570(1988).
Simmons D.,et al.Nature 340:662-662(1989).
Peltz G.A.,et al.Proc. Natl. Acad. Sci. U.S.A. 86:1013-1017(1989).
Scallon B.J.,et al.Proc. Natl. Acad. Sci. U.S.A. 86:5079-5083(1989).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.